{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:07:18Z","timestamp":1789704438120,"version":"4.0.1"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"DOI":"10.1007\/s11899-026-00790-5","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T03:29:38Z","timestamp":1789702178000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Molecular Response, Event-Free Survival, and Treatment-Free Remission in Myeloproliferative Neoplasms: Update and Review with Insights from MPN Asia 2026"],"prefix":"10.1007","volume":"21","author":[{"given":"Ghaith","family":"Abu-Zeinah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela S.","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raajit K.","family":"Rampal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harinder","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Komrokji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsewang","family":"Tashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prithviraj","family":"Bose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Mascarenhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulraheem","family":"Yacoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen T.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Shimoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandi N.","family":"Reeves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennex Hsueh-Lin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef T.","family":"Prchal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Kaushansky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben A.","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"issue":"7","key":"790_CR1","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia. 2022;36(7):1703\u201319. https:\/\/doi.org\/10.1038\/s41375-022-01613-1.","journal-title":"Leukemia"},{"issue":"9","key":"790_CR2","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1002\/ajh.27002","volume":"98","author":"A Tefferi","year":"2023","unstructured":"Tefferi A, Barbui T. Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98(9):1465\u201387. https:\/\/doi.org\/10.1002\/ajh.27002.","journal-title":"Am J Hematol"},{"issue":"4","key":"790_CR3","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/ajh.27216","volume":"99","author":"A Tefferi","year":"2024","unstructured":"Tefferi A, Vannucchi AM, Barbui T. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024;99(4):697\u2013718. https:\/\/doi.org\/10.1002\/ajh.27216.","journal-title":"Am J Hematol"},{"issue":"5","key":"790_CR4","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/ajh.26857","volume":"98","author":"A Tefferi","year":"2023","unstructured":"Tefferi A. Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98(5):801\u201321. https:\/\/doi.org\/10.1002\/ajh.26857.","journal-title":"Am J Hematol"},{"issue":"19","key":"790_CR5","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1200\/JCO.22.01935","volume":"41","author":"CN Harrison","year":"2023","unstructured":"Harrison CN, Nangalia J, Boucher R, et al. Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial. J Clin Oncol. 2023;41(19):3534\u201344. https:\/\/doi.org\/10.1200\/JCO.22.01935.","journal-title":"J Clin Oncol"},{"issue":"5","key":"790_CR6","doi-asserted-by":"publisher","first-page":"e70137","DOI":"10.1002\/hem3.70137","volume":"9","author":"JJ Kiladjian","year":"2025","unstructured":"Kiladjian JJ, Klade C, Georgiev P, PROUD-PV Study Group, et al. Event-free survival in early polycythemia vera patients correlates with molecular response to ropeginterferon alfa-2b or hydroxyurea\/best available therapy (PROUD-PV\/CONTINUATION-PV). HemaSphere. 2025;9(5):e70137. https:\/\/doi.org\/10.1002\/hem3.70137.","journal-title":"HemaSphere"},{"issue":"11","key":"790_CR7","doi-asserted-by":"publisher","first-page":"3920","DOI":"10.1182\/bloodadvances.2026019612","volume":"10","author":"H Gill","year":"2026","unstructured":"Gill H, Au L, Yim R, et al. Ropeginterferon alfa-2b for prefibrotic myelofibrosis and lower-risk myelofibrosis requiring cytoreduction. Blood Adv. 2026;10(11):3920\u201330. https:\/\/doi.org\/10.1182\/bloodadvances.2026019612.","journal-title":"Blood Adv"},{"issue":"5","key":"790_CR8","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","volume":"32","author":"T Barbui","year":"2018","unstructured":"Barbui T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32(5):1057\u201369. https:\/\/doi.org\/10.1038\/s41375-018-0077-1.","journal-title":"Leukemia"},{"key":"790_CR9","doi-asserted-by":"publisher","unstructured":"Gisslinger H, Klade C, Georgiev P, PROUD-PV Study Group, et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020;7(3):e196\u2013208. https:\/\/doi.org\/10.1016\/S2352-3026(19)30236-4.","DOI":"10.1016\/S2352-3026(19)30236-4"},{"issue":"5","key":"790_CR10","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41375-022-01528-x","volume":"36","author":"JJ Kiladjian","year":"2022","unstructured":"Kiladjian JJ, Klade C, Georgiev P, PROUD-PV Study Group, et al. Long-term outcomes of polycythemia vera patients treated with ropeginterferon alfa-2b. Leukemia. 2022;36(5):1408\u201311. https:\/\/doi.org\/10.1038\/s41375-022-01528-x.","journal-title":"Leukemia"},{"key":"790_CR11","doi-asserted-by":"publisher","first-page":"4829","DOI":"10.1182\/blood-2008-09-176818","volume":"113","author":"G Barosi","year":"2009","unstructured":"Barosi G, Birgegard G, Finazzi G, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood. 2009;113:4829\u201333. https:\/\/doi.org\/10.1182\/blood-2008-09-176818.","journal-title":"Blood"},{"issue":"10","key":"790_CR12","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1038\/s41375-023-02008-6","volume":"37","author":"H Gisslinger","year":"2023","unstructured":"Gisslinger H, Klade C, Georgiev P, PROUD-PV Study Group, et al. Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment. Leukemia. 2023;37(10):2129\u201332. https:\/\/doi.org\/10.1038\/s41375-023-02008-6.","journal-title":"Leukemia"},{"issue":"2","key":"790_CR13","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1182\/bloodadvances.2025017938","volume":"10","author":"S Suo","year":"2026","unstructured":"Suo S, Fu R, Qin A, et al. Long-term efficacy and safety of ropeginterferon alfa-2b under its HIDAT regimen for the treatment of polycythemia vera. Blood Adv. 2026;10(2):507\u201310. https:\/\/doi.org\/10.1182\/bloodadvances.2025017938.","journal-title":"Blood Adv"},{"issue":"6","key":"790_CR14","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1007\/s00277-024-05754-4","volume":"103","author":"CC Chen","year":"2024","unstructured":"Chen CC, Chen JL, Lin AJH, Yu LHL, Hou HA. Association of JAK2V617F allele burden and clinical correlates in polycythemia vera: a systematic review and meta-analysis. Ann Hematol. 2024;103(6):1947\u201365. https:\/\/doi.org\/10.1007\/s00277-024-05754-4.","journal-title":"Ann Hematol"},{"issue":"18","key":"790_CR15","doi-asserted-by":"publisher","first-page":"5477","DOI":"10.1182\/bloodadvances.2022007128","volume":"6","author":"G Abu-Zeinah","year":"2022","unstructured":"Abu-Zeinah G, Di Giandomenico S, Choi D, et al. Hematopoietic fitness of JAK2V617F myeloproliferative neoplasms is linked to clinical outcome. Blood Adv. 2022;6(18):5477\u201381.","journal-title":"Blood Adv"},{"issue":"1","key":"790_CR16","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s43018-022-00486-8","volume":"4","author":"T Kong","year":"2023","unstructured":"Kong T, Laranjeira ABA, Yang K, et al. DUSP6 mediates resistance to JAK2 inhibition and drives leukemic progression. Nat Cancer. 2023;4(1):108\u201327. https:\/\/doi.org\/10.1038\/s43018-022-00486-8.","journal-title":"Nat Cancer"},{"key":"790_CR17","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/s41467-024-55643-7","volume":"16","author":"T Kong","year":"2025","unstructured":"Kong T, Laranjeira ABA, Letson CT, et al. RSK1 is an exploitable dependency in myeloproliferative neoplasms and secondary acute myeloid leukemia. Nat Commun. 2025;16:492. https:\/\/doi.org\/10.1038\/s41467-024-55643-7.","journal-title":"Nat Commun"},{"issue":"22","key":"790_CR18","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1182\/blood.2023021503","volume":"142","author":"JP Bewersdorf","year":"2023","unstructured":"Bewersdorf JP, How J, Masarova L, Bose P, Pemmaraju N, Mascarenhas J, et al. Moving toward disease modification in polycythemia vera. Blood. 2023;142(22):1859\u201370. https:\/\/doi.org\/10.1182\/blood.2023021503.","journal-title":"Blood"},{"issue":"6","key":"790_CR19","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1111\/bcp.16043","volume":"90","author":"A Qin","year":"2024","unstructured":"Qin A, Wu D, Li Y, et al. Exposure-efficacy and exposure-safety analyses of ropeginterferon alfa-2b treatment in patients with polycythaemia vera. Br J Clin Pharmacol. 2024;90(6):1493\u2013502. https:\/\/doi.org\/10.1111\/bcp.16043.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"790_CR20","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/ng.334","volume":"41","author":"AV Jones","year":"2009","unstructured":"Jones AV, Chase A, Silver RT, et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet. 2009;41(4):446\u20139. https:\/\/doi.org\/10.1038\/ng.334.","journal-title":"Nat Genet"},{"issue":"7","key":"790_CR21","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa1412098","volume":"372","author":"CA Ortmann","year":"2015","unstructured":"Ortmann CA, Kent DG, Nangalia J, et al. Effect of mutation order on myeloproliferative neoplasms. N Engl J Med. 2015;372(7):601\u201312. https:\/\/doi.org\/10.1056\/NEJMoa1412098.","journal-title":"N Engl J Med"},{"issue":"15","key":"790_CR22","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","volume":"379","author":"J Grinfeld","year":"2018","unstructured":"Grinfeld J, Nangalia J, Baxter EJ, et al. Classification and personalized prognosis in myeloproliferative neoplasms. N Engl J Med. 2018;379(15):1416\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1716614.","journal-title":"N Engl J Med"},{"issue":"3","key":"790_CR23","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1158\/2159-8290.CD-14-0736","volume":"5","author":"M Kleppe","year":"2015","unstructured":"Kleppe M, Kwak M, Koppikar P, et al. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer Discov. 2015;5(3):316\u201331. https:\/\/doi.org\/10.1158\/2159-8290.CD-14-0736.","journal-title":"Cancer Discov"},{"issue":"10","key":"790_CR24","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1038\/s41375-018-0207-9","volume":"32","author":"YZ Ginzburg","year":"2018","unstructured":"Ginzburg YZ, Feola M, Zimran E, et al. Dysregulated iron metabolism in polycythemia vera: etiology and consequences. Leukemia. 2018;32(10):2105\u201316. https:\/\/doi.org\/10.1038\/s41375-018-0207-9.","journal-title":"Leukemia"},{"issue":"1","key":"790_CR25","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1208500","volume":"368","author":"R Marchioli","year":"2013","unstructured":"Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1208500.","journal-title":"N Engl J Med"},{"issue":"4","key":"790_CR26","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/ng1019","volume":"32","author":"SO Ang","year":"2002","unstructured":"Ang SO, Chen H, Hirota K, et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet. 2002;32(4):614\u201321. https:\/\/doi.org\/10.1038\/ng1019.","journal-title":"Nat Genet"},{"issue":"10","key":"790_CR27","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1056\/NEJMoa1205119","volume":"367","author":"Z Zhuang","year":"2012","unstructured":"Zhuang Z, Yang C, Lorenzo F, et al. Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N Engl J Med. 2012;367(10):922\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1205119.","journal-title":"N Engl J Med"},{"issue":"2","key":"790_CR28","doi-asserted-by":"publisher","first-page":"E37","DOI":"10.1002\/ajh.26402","volume":"97","author":"BN Reeves","year":"2022","unstructured":"Reeves BN, Kim SJ, Song J, et al. Tissue factor activity is increased in neutrophils from JAK2 V617F-mutated essential thrombocythemia and polycythemia vera patients. Am J Hematol. 2022;97(2):E37\u201340. https:\/\/doi.org\/10.1002\/ajh.26402.","journal-title":"Am J Hematol"},{"issue":"6","key":"790_CR29","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1182\/bloodadvances.2019001379","volume":"4","author":"R Gangaraju","year":"2020","unstructured":"Gangaraju R, Song J, Kim SJ, et al. Thrombotic, inflammatory, and HIF-regulated genes and thrombosis risk in polycythemia vera and essential thrombocythemia. Blood Adv. 2020;4(6):1115\u201330. https:\/\/doi.org\/10.1182\/bloodadvances.2019001379.","journal-title":"Blood Adv"},{"issue":"5","key":"790_CR30","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1182\/bloodadvances.2022008052","volume":"7","author":"J Song","year":"2023","unstructured":"Song J, Kim SJ, Gollamudi J, Thiagarajan P, Prchal JT. Downregulated KLF2 in polycythemia vera and essential thrombocythemia induces prothrombotic gene expression. Blood Adv. 2023;7(5):712\u20137. https:\/\/doi.org\/10.1182\/bloodadvances.2022008052.","journal-title":"Blood Adv"},{"issue":"8","key":"790_CR31","doi-asserted-by":"publisher","first-page":"3294","DOI":"10.1182\/blood-2002-07-2287","volume":"101","author":"E Liu","year":"2003","unstructured":"Liu E, Jelinek J, Pastore YD, Guan Y, Prchal JF, Prchal JT. Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin. Blood. 2003;101(8):3294\u2013301. https:\/\/doi.org\/10.1182\/blood-2002-07-2287.","journal-title":"Blood"},{"issue":"8","key":"790_CR32","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1038\/s41375-018-0080-6","volume":"32","author":"T Tashi","year":"2018","unstructured":"Tashi T, Swierczek S, Kim SJ, et al. Pegylated interferon Alfa-2a and hydroxyurea in polycythemia vera and essential thrombocythemia: differential cellular and molecular responses. Leukemia. 2018;32(8):1830\u20133. https:\/\/doi.org\/10.1038\/s41375-018-0080-6.","journal-title":"Leukemia"},{"issue":"3","key":"790_CR33","doi-asserted-by":"publisher","first-page":"100087","DOI":"10.1016\/j.bneo.2025.100087","volume":"2","author":"Y Tahira","year":"2025","unstructured":"Tahira Y, Shide K, Kameda T, et al. TYK2 is essential for the therapeutic effect of IFN-? in Jak2V617F-induced murine myeloproliferative neoplasms. Blood Neoplasia. 2025;2(3):100087. https:\/\/doi.org\/10.1016\/j.bneo.2025.100087.","journal-title":"Blood Neoplasia"},{"issue":"10","key":"790_CR34","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41408-018-0133-0","volume":"8","author":"E Verger","year":"2018","unstructured":"Verger E, Soret-Dulphy J, Maslah N, et al. Ropeginterferon alfa-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo. Blood Cancer J. 2018;8(10):94. https:\/\/doi.org\/10.1038\/s41408-018-0133-0.","journal-title":"Blood Cancer J"},{"key":"790_CR35","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1089\/jir.1997.17.355","volume":"17","author":"XQ Qin","year":"1997","unstructured":"Qin XQ, Runkel L, Deck C, et al. Interferon-beta induces S phase accumulation selectively in human transformed cells. J Interferon cytokine Res. 1997;17:355\u201367. https:\/\/doi.org\/10.1089\/jir.1997.17.355.","journal-title":"J Interferon cytokine Res"},{"key":"790_CR36","doi-asserted-by":"publisher","first-page":"574224","DOI":"10.2147\/DDDT.S574224","volume":"20","author":"A Qin","year":"2026","unstructured":"Qin A. Beyond oncogenes: Selectively targeting whole-tumor cell growth regulation. Drug Des Devel Ther. 2026;20:574224. https:\/\/doi.org\/10.2147\/DDDT.S574224.","journal-title":"Drug Des Devel Ther"},{"key":"790_CR37","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1089\/10799900260442511","volume":"22","author":"C Kaynor","year":"2002","unstructured":"Kaynor C, Xin M, Wakefield J, Barsoum J, Qin XQ. Direct evidence that IFN-beta functions as a tumor-suppressor protein. J Interferon Cytokine Res. 2002;22:1089\u201398. https:\/\/doi.org\/10.1089\/10799900260442511.","journal-title":"J Interferon Cytokine Res"},{"issue":"5","key":"790_CR38","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.clinthera.2024.03.005","volume":"46","author":"A Qin","year":"2024","unstructured":"Qin A. Mechanism of action of ropeginterferon alfa-2b in polycythemia vera treatment. Clin Ther. 2024;46(5):439\u201340. https:\/\/doi.org\/10.1016\/j.clinthera.2024.03.005.","journal-title":"Clin Ther"},{"key":"790_CR39","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-2994-x","author":"AM Vannucchi","year":"2017","unstructured":"Vannucchi AM, Verstovsek S, Guglielmelli P, et al. Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study. Ann Hematol. 2017. https:\/\/doi.org\/10.1007\/s00277-017-2994-x.","journal-title":"Ann Hematol"},{"issue":"3","key":"790_CR40","doi-asserted-by":"publisher","first-page":"e175","DOI":"10.1016\/S2352-3026(20)30373-2","volume":"8","author":"T Barbui","year":"2021","unstructured":"Barbui T, Vannucchi AM, De Stefano V, et al. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial. Lancet Haematol. 2021;8(3):e175\u201384. https:\/\/doi.org\/10.1016\/S2352-3026(20)30373-2.","journal-title":"Lancet Haematol"},{"issue":"6","key":"790_CR41","doi-asserted-by":"publisher","first-page":"EVIDoa2200335","DOI":"10.1056\/EVIDoa2200335","volume":"2","author":"T Barbui","year":"2023","unstructured":"Barbui T, Vannucchi AM, De Stefano V, et al. Ropeginterferon versus standard therapy for low-risk patients with polycythemia vera. NEJM Evid. 2023;2(6):EVIDoa2200335. https:\/\/doi.org\/10.1056\/EVIDoa2200335.","journal-title":"NEJM Evid"},{"issue":"2","key":"790_CR42","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s12185-024-03804-1","volume":"120","author":"K Shimoda","year":"2024","unstructured":"Shimoda K, Qin A, Komatsu N, Kirito K. Efficacy and safety outcomes in Japanese patients with low-risk polycythemia vera treated with ropeginterferon alfa-2b. Int J Hematol. 2024;120(2):151\u20136.","journal-title":"Int J Hematol"},{"issue":"6","key":"790_CR43","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s12185-024-03846-5","volume":"120","author":"K Kirito","year":"2024","unstructured":"Kirito K, Sugimoto Y, Gotoh A, et al. Long-term safety and efficacy of ropeginterferon alfa-2b in Japanese patients with polycythemia vera. Int J Hematol. 2024;120(6):675\u201383.","journal-title":"Int J Hematol"},{"key":"790_CR44","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s40164-023-00415-0","volume":"12","author":"J Jin","year":"2023","unstructured":"Jin J, Zhang L, Qin A, et al. A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera. Exp Hematol Oncol. 2023;12:55. https:\/\/doi.org\/10.1186\/s40164-023-00415-0.","journal-title":"Exp Hematol Oncol"},{"issue":"6","key":"790_CR45","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1007\/s12185-026-04163-9","volume":"123","author":"T Inano","year":"2026","unstructured":"Inano T, Sugimoto Y, Ohishi K, et al. Efficacy and safety of a three-step dose escalation regimen of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: a phase 3b, single-arm, multicenter study. Int J Hematol. 2026;123(6):848\u201357. https:\/\/doi.org\/10.1007\/s12185-026-04163-9.","journal-title":"Int J Hematol"},{"key":"790_CR46","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1111\/bjh.19846","volume":"205","author":"S Suo","year":"2024","unstructured":"Suo S, Fu RF, Qin A, et al. Molecular remission uncoupled with complete haematological response in polycythaemia vera treatment with ropeginterferon alfa-2b. Br J Haematol. 2024;205:2510\u20134. https:\/\/doi.org\/10.1111\/bjh.19846.","journal-title":"Br J Haematol"},{"issue":"1","key":"790_CR47","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/hemato7010002","volume":"7","author":"SN Pei","year":"2026","unstructured":"Pei SN, Chen CGS, Kao HW, et al. High-initial-dose accelerated titration regimen of ropeginterferon alfa-2b in younger patients with polycythemia vera and essential thrombocythemia: a consecutive case series study. Hemato. 2026;7(1):2. https:\/\/doi.org\/10.3390\/hemato7010002.","journal-title":"Hemato"},{"issue":"3","key":"790_CR48","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1002\/ijc.35411","volume":"157","author":"SY Yoon","year":"2025","unstructured":"Yoon SY, Yoon SS, Yang DH, et al. Hematologic and molecular responses to ropeginterferon alfa-2b therapy of polycythemia vera: 48-week results from a prospective study. Int J Cancer. 2025;157(3):526\u201333. https:\/\/doi.org\/10.1002\/ijc.35411.","journal-title":"Int J Cancer"},{"key":"790_CR49","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s44313-024-00026-6","volume":"59","author":"SY Yoon","year":"2024","unstructured":"Yoon SY, Lee SE. Treatment with ropeginterferon alfa-2b in patients with hydroxyurea resistant or intolerant polycythemia vera in South Korea: one-year results from a phase 2 study. Blood Res. 2024;59:23. https:\/\/doi.org\/10.1007\/s44313-024-00026-6.","journal-title":"Blood Res"},{"key":"790_CR50","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s44313-025-00110-5","volume":"60","author":"SE Lee","year":"2025","unstructured":"Lee SE, Yoon SY, Kim SY, et al. A comparative study of hematologic response to ropeginterferon alfa-2b in hydroxyurea-resistant or intolerant polycythemia vera: a real-world data-based analysis. Blood Res. 2025;60:61. https:\/\/doi.org\/10.1007\/s44313-025-00110-5.","journal-title":"Blood Res"},{"key":"790_CR51","doi-asserted-by":"publisher","first-page":"e7166","DOI":"10.1002\/cam4.7166","volume":"13","author":"CC Chen","year":"2024","unstructured":"Chen CC, Kuo MC, Wang YH, et al. Treatment outcome and germline predictive factors of ropeginterferon alpha-2b in myeloproliferative neoplasm patients. Cancer Med. 2024;13:e7166. https:\/\/doi.org\/10.1002\/cam4.7166.","journal-title":"Cancer Med"},{"key":"790_CR52","doi-asserted-by":"publisher","first-page":"1455979","DOI":"10.3389\/fphar.2024.1455979","volume":"15","author":"A Qin","year":"2024","unstructured":"Qin A, Wu D, Liao J, et al. Ethnic sensitivity analyses of pharmacokinetics, efficacy and safety in polycythemia vera treatment with ropeginterferon alfa-2b. Front Pharmacol. 2024;15:1455979. https:\/\/doi.org\/10.3389\/fphar.2024.1455979.","journal-title":"Front Pharmacol"},{"issue":"15","key":"790_CR53","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1182\/blood-2015-04-637280","volume":"126","author":"H Gisslinger","year":"2015","unstructured":"Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, et al. Ropeginterferon alfa-2b, a novel IFN\u03b1-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood. 2015;126(15):1762\u20139. https:\/\/doi.org\/10.1182\/blood-2015-04-637280.","journal-title":"Blood"},{"issue":"7","key":"790_CR54","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.3324\/haematol.2025.288404","volume":"111","author":"BN Reeves","year":"2026","unstructured":"Reeves BN, Song J, Leier A, et al. Metformin alleviates side effects and supports the resumption of interferon therapy in polycythemia vera and essential thrombocythemia. Haematologica. 2026;111(7):2397\u2013402. https:\/\/doi.org\/10.3324\/haematol.2025.288404.","journal-title":"Haematologica"},{"issue":"Suppl 1","key":"790_CR55","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1182\/blood-2020-141223","volume":"136","author":"RD De Oliveira","year":"2020","unstructured":"De Oliveira RD, Soret-Dulphy J, Zhao L-P, et al. Interferon-alpha (IFN) therapy discontinuation is feasible in myeloproliferative neoplasm (MPN) patients with complete hematological remission. Blood. 2020;136(Suppl 1):35\u20136.","journal-title":"Blood"},{"issue":"6","key":"790_CR56","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1111\/bjh.70198","volume":"207","author":"R Brown","year":"2025","unstructured":"Brown R, Bennett R, Crean C, et al. The impact of JAK2V617F variant allele frequency in MPN patients following PEGylated interferon alpha discontinuation. Br J Haematol. 2025;207(6):2597\u2013601. https:\/\/doi.org\/10.1111\/bjh.70198.","journal-title":"Br J Haematol"},{"issue":"3","key":"790_CR57","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1007\/s12185-025-04008-x","volume":"122","author":"S Shirane","year":"2025","unstructured":"Shirane S, Inano T, Fukuda Y, et al. Ropeginterferon-alpha2b discontinuation after long-term exposure: four cases from a single institution. Int J Hematol. 2025;122(3):458\u201361. https:\/\/doi.org\/10.1007\/s12185-025-04008-x.","journal-title":"Int J Hematol"},{"key":"790_CR58","doi-asserted-by":"publisher","first-page":"204062072614319","DOI":"10.1177\/20406207261431904","volume":"17","author":"SY Yoon","year":"2026","unstructured":"Yoon SY, Yoon SS, Yang DH, et al. Neutrophil-to-lymphocyte ratio half reduction as a surrogate of molecular response in polycythemia vera treated with ropeginterferon alfa-2b. Ther Adv Hematol. 2026;17:20406207261431904. https:\/\/doi.org\/10.1177\/20406207261431904.","journal-title":"Ther Adv Hematol"},{"key":"790_CR59","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41408-024-01176-7","volume":"14","author":"T Barbui","year":"2024","unstructured":"Barbui T, Carobbio A, Ghirardi A, et al. Neutrophil-to-lymphocyte ratio as a prognostic indicator of mortality in polycythemia vera: insights from a prospective cohort analysis. Blood Cancer J. 2024;14:195. https:\/\/doi.org\/10.1038\/s41408-024-01176-7.","journal-title":"Blood Cancer J"},{"key":"790_CR60","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/s41408-025-01317-6","volume":"15","author":"T Barbui","year":"2025","unstructured":"Barbui T, Ghirardi A, Empson V, et al. Neutrophil-to-Lymphocyte ratio as surrogate for JAK2V617F suppression and event-free survival in polycythemia vera. Blood Cancer J. 2025;15:132. https:\/\/doi.org\/10.1038\/s41408-025-01317-6.","journal-title":"Blood Cancer J"},{"issue":"5","key":"790_CR61","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1182\/bloodadvances.2025018011","volume":"10","author":"T Barbui","year":"2026","unstructured":"Barbui T, Scandura JM. Toward new therapy end points in polycythemia vera: targeting clonal and inflammatory pathways. Blood Adv. 2026;10(5):1473\u201380. https:\/\/doi.org\/10.1182\/bloodadvances.2025018011.","journal-title":"Blood Adv"},{"issue":"1","key":"790_CR62","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1182\/blood-2006-12-062125","volume":"110","author":"A Theocharides","year":"2007","unstructured":"Theocharides A, Boissinot M, Girodon F, et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood. 2007;110(1):375\u20139. https:\/\/doi.org\/10.1182\/blood-2006-12-062125.","journal-title":"Blood"},{"issue":"1","key":"790_CR63","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11899-025-00758-x","volume":"20","author":"M Duan","year":"2025","unstructured":"Duan M, Bose P, Hunter AM, Qin A, Chang L, Li W, Wu D, Rampal RK. Emerging significance and implications of a durable complete molecular remission in the treatment of polycythemia vera. Curr Hematol Malig Rep. 2025;20(1):13. https:\/\/doi.org\/10.1007\/s11899-025-00758-x.","journal-title":"Curr Hematol Malig Rep"},{"issue":"Suppl 1","key":"790_CR64","doi-asserted-by":"publisher","first-page":"6722","DOI":"10.1182\/blood-2022-162621","volume":"140","author":"S Rai","year":"2022","unstructured":"Rai S, Stetka J, Usart M, et al. The second generation type II JAK2 inhibitor, AJ1-10502, demonstrates enhanced selectivity, improved therapeutic efficacy and reduced mutant cell fraction compared to type I JAK2 inhibitors in models of myeloproliferative neoplasms (MPNs). Blood. 2022;140(Suppl 1):6722\u201323.","journal-title":"Blood"},{"issue":"5","key":"790_CR65","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1158\/2643-3230.BCD-22-0189","volume":"4","author":"PC Nair","year":"2023","unstructured":"Nair PC, Piehler J, Tvorogov D, Ross DM, Lopez AF, Gotlib J, et al. Next-generation JAK2 inhibitors for the treatment of myeloproliferative neoplasms: lessons from structure-based drug discovery approaches. Blood Cancer Discov. 2023;4(5):352\u201364.","journal-title":"Blood Cancer Discov"},{"issue":"20","key":"790_CR66","doi-asserted-by":"publisher","first-page":"5416","DOI":"10.1182\/bloodadvances.2024013170","volume":"8","author":"AL S\u00f8rensen","year":"2024","unstructured":"S\u00f8rensen AL, Skov V, Kj\u00e6r L, et al. Combination therapy with ruxolitinib and pegylated interferon alfa-2a in newly diagnosed patients with polycythemia vera. Blood Adv. 2024;8(20):5416\u201325.","journal-title":"Blood Adv"},{"key":"790_CR67","doi-asserted-by":"publisher","unstructured":"Kremyanskaya M, Kuykendall AT, Pemmaraju N, REVIVE Trial Investigators, et al. Rusfertide, a hepcidin mimetic, for control of erythrocytosis in polycythemia vera. N Engl J Med. 2024;390(8):723\u201335. https:\/\/doi.org\/10.1056\/NEJMoa2308809.","DOI":"10.1056\/NEJMoa2308809"},{"issue":"12","key":"790_CR68","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1182\/blood.2025028643","volume":"147","author":"M Kremyanskaya","year":"2026","unstructured":"Kremyanskaya M, Ginzburg YZ, Hoffman R. Modulators of the hepcidin pathway in polycythemia vera and myelofibrosis. Blood. 2026;147(12):1278\u201388. https:\/\/doi.org\/10.1182\/blood.2025028643.","journal-title":"Blood"},{"issue":"10","key":"790_CR69","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","volume":"123","author":"E Rumi","year":"2014","unstructured":"Rumi E, Pietra D, Ferretti V, et al. Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014;123(10):1544\u201351. https:\/\/doi.org\/10.1182\/blood-2013-11-539098.","journal-title":"Blood"},{"issue":"13","key":"790_CR70","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1182\/blood.2023023428","volume":"143","author":"P Guglielmelli","year":"2024","unstructured":"Guglielmelli P, Szuber N, Gangat N, et al. CALR mutation burden in essential thrombocythemia and disease outcome. Blood. 2024;143(13):1310\u20134. https:\/\/doi.org\/10.1182\/blood.2023023428.","journal-title":"Blood"},{"key":"790_CR71","doi-asserted-by":"publisher","first-page":"e487","DOI":"10.1038\/bcj.2016.98","volume":"6","author":"M Haider","year":"2016","unstructured":"Haider M, Elala YC, Gangat N, Hanson CA, Tefferi A. MPL mutations and palpable splenomegaly are independent risk factors for fibrotic progression in essential thrombocythemia. Blood Cancer J. 2016;6:e487. https:\/\/doi.org\/10.1038\/bcj.2016.98.","journal-title":"Blood Cancer J"},{"issue":"1","key":"790_CR72","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41408-024-01079-7","volume":"14","author":"G Abu-Zeinah","year":"2024","unstructured":"Abu-Zeinah G, Erdos K, Lee N, Lebbe A, Bouhali I, Khalid M, Silver RT, Scandura JM. Are thrombosis, progression, and survival in ET predictable? Blood Cancer J. 2024;14(1):103. https:\/\/doi.org\/10.1038\/s41408-024-01079-7.","journal-title":"Blood Cancer J"},{"key":"790_CR73","doi-asserted-by":"publisher","unstructured":"Mesa R, Gill H, Zhang L, SURPASS-ET Study Group, et al. Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study. Lancet Haematol. 2025;12(11):e862\u201375. https:\/\/doi.org\/10.1016\/S2352-3026(25)00264-9.","DOI":"10.1016\/S2352-3026(25)00264-9"},{"key":"790_CR74","doi-asserted-by":"publisher","first-page":"101529","DOI":"10.1016\/j.lana.2026.101529","volume":"61","author":"BN Reeves","year":"2026","unstructured":"Reeves BN, El Chaer F, Foltz L, et al. Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EXCEED-ET). Lancet Reg Health Am. 2026;61:101529. https:\/\/doi.org\/10.1016\/j.lana.2026.101529.","journal-title":"Lancet Reg Health Am"},{"key":"790_CR75","doi-asserted-by":"publisher","first-page":"204062072513596","DOI":"10.1177\/20406207251359651","volume":"16","author":"MS Yu","year":"2025","unstructured":"Yu MS, Yu LHL, Huang SH, et al. Real-world characteristics and treatment patterns in essential thrombocythemia: a population-based cross-sectional study in Taiwan between 2020 and 2021. Ther Adv Hematol. 2025;16:20406207251359651. https:\/\/doi.org\/10.1177\/20406207251359651.","journal-title":"Ther Adv Hematol"},{"key":"790_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2026.01.051","author":"AJH Lin","year":"2026","unstructured":"Lin AJH, Huang CE, Tsai TH, et al. Five-year population-based study of essential thrombocythemia in Taiwan: epidemiology, treatment patterns, and sex-based disparities. J Formos Med Assoc. 2026. https:\/\/doi.org\/10.1016\/j.jfma.2026.01.051.","journal-title":"J Formos Med Assoc"},{"issue":"10","key":"790_CR77","doi-asserted-by":"publisher","first-page":"3494","DOI":"10.1182\/bloodadvances.2025017575","volume":"10","author":"H Gill","year":"2026","unstructured":"Gill H, Palandri F, Ross DM, et al. Phase 2 study of the lysine-specific demethylase 1 inhibitor bomedemstat for essential thrombocythemia. Blood Adv. 2026;10(10):3494\u2013504. https:\/\/doi.org\/10.1182\/bloodadvances.2025017575.","journal-title":"Blood Adv"},{"issue":"Suppl 1","key":"790_CR78","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1182\/blood-2025-1024","volume":"146","author":"V Gupta","year":"2025","unstructured":"Gupta V, Mascarenhas J, Ali H, et al. Safety and efficacy of INCA033989, a novel first in class mutant calreticulin-specific monoclonal antibody, in patients with essential thrombocythemia. Blood. 2025;146(Suppl 1):1024\u20135. https:\/\/doi.org\/10.1182\/blood-2025-1024.","journal-title":"Blood"},{"issue":"12","key":"790_CR79","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1182\/blood.2025028642","volume":"147","author":"GS Salzman","year":"2026","unstructured":"Salzman GS, Mullally A. Novel strategies targeting mutant calreticulin in essential thrombocythemia and myelofibrosis. Blood. 2026;147(12):1267\u201377. https:\/\/doi.org\/10.1182\/blood.2025028642.","journal-title":"Blood"},{"issue":"12","key":"790_CR80","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1182\/blood.2025032534","volume":"147","author":"J Gotlib","year":"2026","unstructured":"Gotlib J. Introduction to a review series on the new wave of targeted therapeutics for MPNs. Blood. 2026;147(12):1239\u201342. https:\/\/doi.org\/10.1182\/blood.2025032534.","journal-title":"Blood"},{"key":"790_CR81","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","volume":"36","author":"P Guglielmelli","year":"2018","unstructured":"Guglielmelli P, Lasho TL, Rotunno G, et al. MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary yelofibrosis. J Clin Oncol. 2018;36:310\u20138. https:\/\/doi.org\/10.1200\/JCO.2017.76.4886.","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"790_CR82","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1182\/blood-2024-200997","volume":"144","author":"K Erdos","year":"2024","unstructured":"Erdos K, Alshareef A, Silver RT, Scandura JM, Abu-Zeinah G. Outcomes are similar for combination interferon and tuxolitinib versus ruxolitinib in myelofibrosis: A propensity-score matched study. Blood. 2024;144(Supplement 1):1784. https:\/\/doi.org\/10.1182\/blood-2024-200997.","journal-title":"Blood"},{"issue":"17","key":"790_CR83","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","volume":"36","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Guglielmelli P, Lasho TL, et al. MIPSS70 + version 2.0: mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis. J Clin Oncol. 2018;36(17):1769\u201370. https:\/\/doi.org\/10.1200\/JCO.2018.78.9867.","journal-title":"J Clin Oncol"},{"issue":"3","key":"790_CR84","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1182\/blood.2024025459","volume":"145","author":"H Pasquer","year":"2025","unstructured":"Pasquer H, Kiladjian JJ, Benajiba L. Current myeloproliferative neoplasm scoring systems for clinical practice. Blood. 2025;145(3):257\u201376. https:\/\/doi.org\/10.1182\/blood.2024025459.","journal-title":"Blood"},{"key":"790_CR85","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","volume":"379","author":"J Grinfeld","year":"2018","unstructured":"Grinfeld J, Nangalia J, Baxter EJ, Wedge DC, Angelopoulos N, Cantrill R, et al. Classification and personalized prognosis in myeloproliferative neoplasms. N Engl J Med. 2018;379:1416\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1716614.","journal-title":"N Engl J Med"},{"issue":"11","key":"790_CR86","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1016\/j.leukres.2008.03.015","volume":"32","author":"Y-Y Wu","year":"2008","unstructured":"Wu Y-Y, Hung H-M, Chen T-S, Chao T-Y, Ho C-L. Decreased JAK2 V617F allele burden level in a myelofibrosis with myeloid metaplasia patient with leukemic transformation. Leuk Res. 2008;32(11):1783\u20136. https:\/\/doi.org\/10.1016\/j.leukres.2008.03.015.","journal-title":"Leuk Res"},{"issue":"9","key":"790_CR87","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1007\/s00277-024-05912-8","volume":"103","author":"G Abu-Zeinah","year":"2024","unstructured":"Abu-Zeinah G, Qin A, Gill H, et al. A randomized, double-blind, placebo-controlled phase 3 study to assess efficacy and safety of ropeginterferon alfa-2b in patients with early\/lower-risk primary myelofibrosis. Ann Hematol. 2024;103(9):3573\u201383. https:\/\/doi.org\/10.1007\/s00277-024-05912-8.","journal-title":"Ann Hematol"},{"key":"790_CR88","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025032693","author":"T Uchida","year":"2026","unstructured":"Uchida T, Shide K, Kameda T, et al. Fibrocytes drive JAK2V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia. Blood. 2026. https:\/\/doi.org\/10.1182\/blood.2025032693.","journal-title":"Blood"},{"key":"790_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2025.06.011","author":"YS Chang","year":"2025","unstructured":"Chang YS, Liu CY, Chen YW, et al. Real-world evidence on outcomes and safety of ropeginterferon alfa-2b in patients with myeloproliferative neoplasms: a retrospective cohort study. Clin Lymphoma Myeloma Leuk. 2025. https:\/\/doi.org\/10.1016\/j.clml.2025.06.011.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"790_CR90","unstructured":"Rampal RK, Grosicki S, Chraniuk D et al. Pelabresib plus ruxolitinib in JAK inhibitor-naive myelofibrosis. Nat Med. 2025. Published online March 10, 2025."},{"key":"790_CR91","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-26-01080","author":"P Bose","year":"2026","unstructured":"Bose P, Ali H, Al-Ali HK, et al. Selinexor plus ruxolitinib in Janus kinase inhibitor\u2013na\u00efve myelofibrosis: Phase III SENTRY trial. J Clin Oncol. 2026. https:\/\/doi.org\/10.1200\/JCO-26-01080.","journal-title":"J Clin Oncol"},{"issue":"7","key":"790_CR92","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1080\/14796694.2026.2638989","volume":"22","author":"P Vachhani","year":"2026","unstructured":"Vachhani P, Yacoub A, Rampal R, et al. POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-na\u00efve myelofibrosis patients with a suboptimal response to ruxolitinib. Future Oncol. 2026;22(7):781\u201393. https:\/\/doi.org\/10.1080\/14796694.2026.2638989.","journal-title":"Future Oncol"},{"issue":"26","key":"790_CR93","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1200\/JCO.20.02864","volume":"39","author":"J Mascarenhas","year":"2021","unstructured":"Mascarenhas J, Komrokji RS, Palandri F, et al. Randomized, single-blind, multicenter phase II study of imetelstat versus best available therapy in patients with intermediate-2 or high-risk myelofibrosis relapsed\/refractory to Janus kinase inhibitor. J Clin Oncol. 2021;39(26):2881\u201392. https:\/\/doi.org\/10.1200\/JCO.20.02864.","journal-title":"J Clin Oncol"},{"key":"790_CR94","unstructured":"Gerds AT, Vannucchi AM, Passamonti F et al. Luspatercept for the treatment of anemia in patients with myelofibrosis: results from a phase 2 study. Blood Adv. 2024. Published online."},{"issue":"1","key":"790_CR95","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41408-025-01381-y","volume":"15","author":"M Marchetti","year":"2025","unstructured":"Marchetti M, Vannucchi AM, Mascarenhas JO, et al. European LeukemiaNet criteria for safety and efficacy evaluation of new drugs for myelofibrosis. Blood Cancer J. 2025;15(1):207. https:\/\/doi.org\/10.1038\/s41408-025-01381-y.","journal-title":"Blood Cancer J"},{"issue":"12","key":"790_CR96","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1038\/s41375-025-02754-9","volume":"39","author":"RB Salit","year":"2025","unstructured":"Salit RB, Hexner EO, Gagelmann N, et al. Defining remission following hematopoietic cell transplant for myelofibrosis: an international expert panel consensus. Leukemia. 2025;39(12):2862\u20135. https:\/\/doi.org\/10.1038\/s41375-025-02754-9.","journal-title":"Leukemia"},{"issue":"1","key":"790_CR97","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41408-023-00867-x","volume":"13","author":"JM Lee","year":"2023","unstructured":"Lee JM, Ahn A, Min EJ, Lee SE, Kim M, Kim Y. Monitoring measurable residual disease and chimerism in patients with JAK2 V617F-positive myelofibrosis after allogeneic hematopoietic cell transplantation. Blood Cancer J. 2023;13(1):97. https:\/\/doi.org\/10.1038\/s41408-023-00867-x.","journal-title":"Blood Cancer J"},{"issue":"4","key":"790_CR98","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1111\/bjh.20003","volume":"206","author":"R Nedumannil","year":"2025","unstructured":"Nedumannil R, Karmi T, Blombery P, Szer J, Ritchie DS, Chee LCY. Serial sensitive molecular detection of JAK2 V617F is predictive of relapse after allogeneic stem cell transplantation in patients with myelofibrosis. Br J Haematol. 2025;206(4):1160\u20134. https:\/\/doi.org\/10.1111\/bjh.20003.","journal-title":"Br J Haematol"},{"issue":"5","key":"790_CR99","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/bjh.15059","volume":"183","author":"MV Shah","year":"2018","unstructured":"Shah MV, Patel KP, Luthra R, et al. Sensitive PCR-based monitoring and early detection of relapsed JAK2 V617F myelofibrosis following transplantation. Br J Haematol. 2018;183(5):831\u20135. https:\/\/doi.org\/10.1111\/bjh.15059.","journal-title":"Br J Haematol"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-026-00790-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-026-00790-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-026-00790-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T03:29:45Z","timestamp":1789702185000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-026-00790-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":99,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["790"],"URL":"https:\/\/doi.org\/10.1007\/s11899-026-00790-5","relation":{},"ISSN":["1558-822X"],"issn-type":[{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"assertion":[{"value":"26 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ghaith Abu-Zeinah: received grant to the institution from Pharma&, honoraria for lectures from PharmaEssentia, and travel and meeting support from PharmaEssentia and AOP Orphan; is a consultant for PharmaEssentia, Takeda, Silence Therapeutics, and Incyte; is a board member of Cancer Research & Treatment (CR&T). Gabriela Hobbs: Grants (Incyte); consulting fees (PharmaEssentia, Protagonist, AbbVie, GSK, Pfizer, Novartis, MorphoSys, Cogent, Pharmaxis); monitoring or advisory board (PharmaEssentia, Protagonist, AbbVie, GSK, Pfizer, Novartis, MorphoSys); stock\/stock options (Regeneron Pharmaceuticals). Raajit K. Rampal: Grants (Incyte, Ryvu, MorphoSys, Zentalis); consulting fees (MorphoSys, CTI, GSK, Stemline, Blueprint, SDP, Servier, Zentalis, BMS, Galectco, AbbVie, PharmaEssentia, Cogent, Kartos); honoraria for lectures\/advisory boards (Protagonist, Karyopharm, GSK); monitoring or advisory board (Kartos). Sung-Eun Lee: received consulting\/advisory board fees from BMS, GlaxoSmithKline, Novartis, PharmaEssentia and received institutional grant from PharmaEssentia. Harinder Gill: Consulting fees\/Speaker fees from Abbvie, Bristol Myers Squibb, GSK, MSD, Novartis, PharmaEssentia Corporation and Pfizer, Advisory board for Abbvie, Bristol Myers Squibb, GSK, Novartis, PharmaEssentia Corporation and Pfizer, Research support from Celgene, MSD, Novartis and PharmaEssentia Corporation, Conference support from Bristol Myers Squibb, MSD, Novartis, Otsuka, PharmaEssentia and Pfizer Rami Komrokji: membership on an entity's board of directors or advisory committees for Taiho and Servier; consultancy, membership on an entity's board of directors or advisory committees, and speakers bureau participation for Jazz Pharmaceuticals, Servier, PharmaEssentia, and Sobi; consultancy and membership on an entity's board of directors or advisory committees for AbbVie, Geron, and Daiichi Sankyo; membership on an entity's board of directors or advisory committees for CTI Biopharma and Keros; honoraria and membership on an entity's board of directors or advisory committees for Bristol Myers Squibb (BMS) and DSI; consultancy and membership on an entity's board of directors or advisory committees for Sumitomo Pharma; research funding from BMS; honoraria from Servio; consultancy, membership on an entity's board of directors or advisory committees, and research funding from Celgene\/BMS; consultancy for Genentech and Janssen; consultancy, honoraria, membership on an entity's board of directors or advisory committees, and speakers bureau participation for Rigel; and membership on an entity's board of directors or advisory committees for Novartis. Tsewang Tashi: Blueprint Medicine (clinical trial grants, advisory board), PharmaEssentia (clinical trial grants, research funding, advisory board), Cogent Biosciences (clinical trial grants, advisory board), Integris Health (honoraria for CME talk), Plexus comm (honoraria for CME talk), GLC\/Reach MD (honoraria for CME talk), OncLive (honoraria for online seminars), Italfarmaco (clinical trial grants), Medscape (seminars), Incyte (advisory board), and Telios (clinical trial grants). Prithviraj Bose: Research support: Incyte, BMS, GSK, Merck, Novartis, Kartos, Telios, Geron, Janssen, Ionis, Deciphera, Disc, Takeda, Cogent, Blueprint, Sumitomo, Karyopharm, Ajax (now Lilly). Honoraria\/consulting fees: Incyte, BMS, GSK, Sobi, Merck, Abbvie, Pharma Essentia, Novartis, Geron, Ionis, Deciphera, Disc, Takeda, Cogent, Blueprint, Sumitomo, Karyopharm, Raythera, Damora, Vyne, V6. John Mascarenhas: Grants (PharmaEssentia, Incyte, Novartis, Geron, AbbVie, Kartos, Karyopharm, DISC, SOBI, Italfarmaco Spa, Dompe, BMS); consulting fees (PharmaEssentia, SOBI, Incyte, Roche, Novartis, Blueprint Medicines, Merck, Geron, AbbVie, BMS, Galecto, Sumitomo, Italfarmaco Spa, and Takeda); monitoring or advisory board (Incyte, Galecto, Cogent). Abdulraheem Yacoub: consultancy: Incyte, CTI Pharma (SOBI), PharmaEssentia, Pfizer, Novartis, Servier, ABBVIE, Karyopharm Therapeutics, GSK, Blueprint Medicine, Apellis, Gilead, Notable Labs, and Protagonist; Research funding: CTI Pharma (SOBI), Stemline Therapeutics. Stephen T. Oh: has served as a consultant for Kartos Therapeutics, CTIBioPharma, Celgene\/Bristol Myers Squibb, Disc Medicine, Blueprint Medicines, PharmaEssentia, Constellation, Geron, Abbvie, Sierra Oncology, and Incyte. Kazuya Shimoda: a consultant for Sierra Oncology, Inc. and reports research funding from AbbVie G.K., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Kyowa Kirin Co., Ltd., Mochida Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Otsuka Pharmaceutical Co., Ltd., PharmaEssentia Japan K.K., Shionogi & Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Taisho Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Co., Ltd.; honoraria from Takeda Pharmaceutical Co., Ltd., and Novartis Pharma K.K.; and is a member of an advisory committee for AbbVie G.K. Brandi N Reeves: has received honoraria\/consulting fees from PharmaEssentia, Pint Pharma, Agios, CTI BioPharma, GSK, Incyte, Sobi, Takeda Minghui Duan: no competing interests to declare related to this article. Lennex Hsueh-Lin Yu: employed at PharmaEssentia. Albert Qin: serving as the chief medical officer of PharmaEssentia Corporation. Josef T. Prchal: Research Funding: PharmaEssentia. Kenneth Kaushansky: no competing interests to declare related to this article. Ruben A. Mesa: Consulting fees: Incyte, PharmaEssentia, CTI, AbbVie, GSK, BMS, Genentech.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"21"}}